Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Puma Biotechnology, Inc.NASDAQ: PBYI

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital turns positive

Q1 FY2026 change in working capital was $14.68M, compared with -$4.4M a year earlier. Trailing-twelve-month change in working capital was $9M. Over 3 fiscal years it compounded at -39.0% a year.

Context

  • Change in working capital amounted to 4.4% of revenue in FY2025, up 2.9 pp from a year earlier.
  • Change in working capital grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly change in working capital holds near $14.68M or moves back toward the trailing-twelve-month quarterly average of $2.25M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.68M+324.6% QoQ
Last fiscal yearDec 2025
-$10.08M+185.1% YoY
LTMMar 2026
$9M+148.4% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+433.9%——
1 year+185.1%——
3-year CAGR-39.0%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(10.08M) USD
Year-over-year change
-185.1%

Change in Working Capital vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +148.4% is the highest of 10, against a peer median of -46.2%.
  • Change in working capital amounts to 4.0% of revenue for PBYI, versus a peer median of 19.0%.
PBYI Competitors
Change in Working Capital for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBPNovaBridge BiosciencesLTM Sep 2025CN¥49.9M CNY—-68.6%—
MGNXMacroGenics, Inc.LTM Mar 2026$17.87M USD+67.2%+66.6%11.4%
VSTMVerastem, Inc.LTM Mar 2026$13.17M USD+39.2%+88.2%26.6%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$9M USD+148.4%-39.0%4.0%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$6.52M USD+92.8%-4.1%—
NUVBNuvation Bio Inc.LTM Jun 2026$2.95M USD-350.5%+51.5%1.7%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$1.46M CAD-46.2%+60.6%—
TNGXTango Therapeutics, Inc.LTM Sep 2026$1.38M USD-98.2%+53.7%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$1.38M USD-145.8%-19.2%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$994K USD-13.9%—189.3%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$974K USD-159.1%+130.6%—
Peer median (excluding PBYI) —-46.2%+53.7%19.0%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.13M)2K21.59M30.28M31.11M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
Deferred Income Tax000(7.08M)3.25M
Stock-Based Compensation32.63M11.83M10.25M8.25M6.94M
Change in Working Capital(1.31M)(44.5M)(17.85M)(3.54M)(10.08M)
Accounts Receivables(5.98M)(7.82M)(8.37M)16.35M(21.28M)
Inventory(3.66M)2.58M(2.55M)(1.64M)3.21M
Accounts Payables(902K)(4.73M)449K(1.38M)(453K)
Other Working Capital9.23M(34.52M)(7.38M)(16.86M)8.45M
Other Non-Cash Items7.15M7M1.51M(519K)(358K)
Operating Cash Flow20.65M(15.83M)27.01M38.92M41.8M
Capital Expenditures0(7M)(12.64M)(56K)(71K)
Acquisitions (Net)00000
Purchases of Investments(38.07M)(4.84M)(23.81M)(76.23M)(108.14M)
Sales of Investments27.19M18.94M17.33M55.85M72.02M
Other Investing Activities00(12.5M)00
Investing Cash Flow(10.88M)7.1M(19.13M)(20.44M)(36.19M)
Debt Repayment(1.5M)00(33.33M)(44.44M)
Common Stock Issued012.5M0150K130K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(30.43M)(277K)0(666K)(888K)
Financing Cash Flow(31.93M)12.22M0(33.85M)(45.2M)
Effect of Forex Changes00000
Net Change in Cash(22.16M)3.5M7.88M(15.37M)(39.58M)
Free Cash Flow20.65M(22.83M)14.37M38.86M41.73M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.